Identification and development of synthetic lethal strategies and predictive biomarkers for therapy for MMR Deficient Co

我们的目标是确定和开发治疗一种特殊类型的大肠癌的新方法，这种癌症是由DNA修复的缺陷引起的。目前，约17%的大肠癌病例有证据表明，DNA修复途径失配修复（MMR）存在缺陷。这既影响年轻患者，主要是遗传形式的MMR缺陷，Lynch综合征，也影响老年患者，他们自发地在MMR基因中产生缺陷。利用先进的分子生物学技术来筛选潜在的药物靶点，我们的目标是识别和开发那些可能用于临床治疗MMR缺陷大肠癌的药物，并打算将它们推向药物试验。实验室研究将在癌症研究所进行，临床研究将在皇家马斯登医院进行。随着新的治疗策略的发展，我们也将开发生物标志物。这些物质可以在患者样本中进行测试，以预测它们是否可能对特定治疗产生反应。

We aim to identify and develop new ways of treating a particular type of large bowel cancer, caused by a defect in how DNA is repaired. At present, about 17% of cases of large bowel cancer have evidence of a deficiency in a DNA repair pathway called Mismatch Repair (MMR). This affects both young patients, who mainly have an inherited form of MMR deficiency, Lynch Syndrome, and older patients, who spontaneously develop a defect in one of the MMR genes. Using advanced molecular biology techniques to screen for potential drug targets, we aim to identify and develop those that could be of use in the clinical treatment of MMR deficient large bowel cancer, with the intention of taking them forwards into drug trials. The laboratory research will be based at the Institute of Cancer Research, and the clinical research at The Royal Marsden Hospital. In tandem with the development of new therapeutic strategies, we will also develop biomarkers. These are substances that can be tested in patient samples to predict whether they are likely to respond to a specific treatment or not.